Submit

Login Login

Register Register

Home / Journals / BIOCELL / Online First / doi:10.32604/biocell.2024.048878
Journal Menu
Special lssues
Table of Content

All issues

Online First

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

SAIB Annual Meetings

Open Access

ARTICLE

MAPK9 as a therapeutic target: unveiling ferroptosis in localized prostate cancer progression

CHENG-GONG LUO1,2,#, JIAO ZHANG1,#, YUN-ZHAO AN1, XUAN LIU1, SHUAI-JIE LI1, WEI ZHANG1, KAI LI1, XU ZHAO1, DONG-BO YUAN1, LING-YUE AN1, WEI CHEN2, YE TIAN1,*, BIN XU1,*
1 Department of Urology, Guizhou Provincial People’s Hospital, Guiyang, China
2 Department of Urology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
* Corresponding Author: YE TIAN. Email: email; BIN XU. Email: email
(This article belongs to the Special Issue: Advances in Biomarker Research: Unveiling the Pathways to Precision Medicine)

BIOCELL https://doi.org/10.32604/biocell.2024.048878

Received 21 December 2023; Accepted 23 February 2024; Published online 29 March 2024

Abstract

Background: Ferroptosis, a lipid peroxidation-mediated programmed cell death, is closely linked to tumor development, including prostate cancer (PCa). Despite established connections between ferroptosis and PCa, a comprehensive investigation is essential for understanding its impact on patient prognosis. Methods: A risk model incorporating four ferroptosis-related genes was developed and validated. Elevated risk scores correlated with an increased likelihood of biochemical recurrence (BCR), diminished immune infiltration, and adverse clinicopathological characteristics. To corroborate these results, we performed validation analyses utilizing datasets from both the Cancer Genome Atlas Cohort (TCGA) and the Gene Expression Synthesis Cohort (GEO). Moreover, we conducted further investigations into the pivotal gene identified in our model to explore its impact on tumor characteristics through cell proliferation and invasion assays, as well as animal studies conducted in vivo. Additionally, we conducted further experiments involving ferroptosis-related analysis to validate its association with ferroptosis. Results: The risk model demonstrated exceptional predictive capabilities for prognosis and therapeutic outcomes in PCa patients. Mitogen-activated protein kinase 9 (MAPK9) emerged as a crucial gene within the model. In vivo and in vitro experiments explored MAPK9’s role in ferroptosis and its influence on tumor migration and proliferation. Conclusion: The findings provide a novel perspective for advancing ferroptosis exploration in PCa, bridging basic research and clinical applications.

Keywords

Ferroptosis; Biochemical recurrence; Prostate cancer; TCGA; GEO; MAPK9

  • 230

    View

  • 54

    Download

  • 0

    Like

Related articles
Copyright© 2024 Tech Science Press
© 1997-2024 TSP (Henderson, USA) unless otherwise stated

Share Link